China Biologic Products Holdings, Inc. (NASDAQ:CBPO) provides blood products and operates profitably. However, sales have fallen recently causing uncertainty over the company's future growth prospects. The stock is quite expensive and with the uncertainty, I'm on the sidelines for now.
Financials
China Biologic has produced strong growth over the last decade and operates with high margins. Over the last decade, the company's profit margins have averaged around 25% and its return on equity has averaged around 24%.
China Biologic's operates with low debt with its total liabilities representing only 8% of its total